Prosight Management, LP Uni Qure N.V. Transaction History

Prosight Management, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$29.24 - $42.03 $1.58 Million - $2.27 Million	-53,900 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$35.35 - $50.67 $4.15 Million - $5.96 Million	-117,529 Reduced 68.56%	53,900 $1.95 Million
Q3 2020 Nov 13, 2020	BUY	$35.98 - $47.66 $1.02 Million - $1.35 Million	28,300 Added 19.77%	171,429 $6.31 Million
Q2 2020 Aug 14, 2020	SELL	$45.06 - $67.74 $4.62 Million - $6.94 Million	-102,435 Reduced 41.71%	143,129 $6.45 Million
Q1 2020 May 15, 2020	BUY	$40.01 - $73.97 $322,640 - $596,494	8,064 Added 3.4%	245,564 $11.7 Million
Q4 2019 Feb 14, 2020	SELL	$37.13 - $74.62 $3.4 Million - $6.83 Million	-91,478 Reduced 27.81%	237,500 $17 Million
Q3 2019 Nov 14, 2019	BUY	$39.36 - $76.8 $8.23 Million - $16 Million	208,978 Added 174.15%	328,978 $12.9 Million
Q2 2019 Aug 14, 2019	BUY	$52.76 - $82.19 $6.33 Million - $9.86 Million	120,000 New	120,000 $9.38 Million
Q2 2018 Aug 14, 2018	SELL	$21.96 - $39.94 $748,836 - $1.36 Million	-34,100 Closed	0 $0
Q1 2018 May 14, 2018	SELL	$17.1 - $26.61 $4.29 Million - $6.67 Million	-250,617 Reduced 88.02%	34,100 $801,000
Q4 2017 Feb 13, 2018	BUY	$9.47 - $19.59 $2.7 Million - $5.58 Million	284,717	284,717 $5.58 Million

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.